Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc. (Delaware)

Grade Last Price % Change Price Change
grade D 0.485 6.36% 0.03
ATNM closed up 6.36 percent on Friday, January 18, 2019, on 2.09 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
10 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ATNM trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 18 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Above Upper BB Strength 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 50 DMA Resistance Bearish 6.36%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.36%
Jan 17 Pocket Pivot Bullish Swing Setup 6.36%
Jan 17 Doji - Bearish? Reversal 6.36%
Jan 16 20 DMA Support Bullish 12.79%

Older signals for ATNM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Is ATNM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 17 Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated
Jan 16 Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
Jan 3 Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
Dec 27 Oppenheimer sees 1H19 risk for smid-cap biotech
Dec 21 How Does Investing In Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Impact The Volatility Of Your Portfolio?
Dec 4 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
Dec 3 Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
Dec 2 The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Nov 23 Key events next week - healthcare
Nov 19 Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
See more ATNM news...
Indicators
Indicator Value
52 Week High 0.865
52 Week Low 0.33
Average Volume 779,069
200-Day Moving Average 0.5512
50-Day Moving Average 0.4601
20-Day Moving Average 0.4279
10-Day Moving Average 0.4468
Average True Range 0.0379
ADX 18.56
+DI 25.8526
-DI 14.0569
Chandelier Exit (Long, 3 ATRs ) 0.4063
Chandelier Exit (Short, 3 ATRs ) 0.4737
Upper Bollinger Band 0.4845
Lower Bollinger Band 0.3713
Percent B (%b) 1.0
BandWidth 26.454779
MACD Line -0.0014
MACD Signal Line -0.01
MACD Histogram 0.0086
Fundamentals Value
Market Cap 38.81 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -0.93
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.58
Resistance 3 (R3) 0.58 0.55 0.57
Resistance 2 (R2) 0.55 0.53 0.55 0.56
Resistance 1 (R1) 0.52 0.51 0.54 0.52 0.56
Pivot Point 0.49 0.49 0.50 0.49 0.49
Support 1 (S1) 0.45 0.46 0.47 0.45 0.41
Support 2 (S2) 0.42 0.45 0.42 0.41
Support 3 (S3) 0.39 0.42 0.40
Support 4 (S4) 0.39